November 6, 2023
There has been unprecedented demand for Beyfortus™ (nirsevimab-alip) 50 mg and 100 mg Injection. For the first time in history, health care providers are able to help protect an extraordinary number of infants against respiratory syncytial virus (RSV) disease.
Despite an aggressive supply plan built to outperform past pediatric immunization launches, demand for this product, in both the 50 and 100 mg doses, has been higher than anticipated.
We previously communicated that new orders for the 100 mg dose were no longer being accepted, as the demand exceeded the available supply for the season. Currently, due to demand, we are carefully managing distribution of the 50 mg doses in the private market to fulfill existing orders and provide equitable access to remaining doses. Sanofi is in contact with providers about distribution plans.
Sanofi is also in close collaboration with the Centers for Disease Control and Prevention, which is working to ensure equitable distribution of available doses through the Vaccines for Children Program.
We are working with our alliance partner AstraZeneca, in charge of manufacturing, to deliver available doses to the market as we continue to explore solutions to address this exceptional demand.
Beyfortus is a prescription medicine used to help prevent a serious lung disease caused by Respiratory Syncytial Virus (RSV) in:
IMPORTANT SAFETY INFORMATION
Your child should not take Beyfortus if your child has a history of serious allergic reactions to nirsevimab-alip or any of the ingredients in Beyfortus.
Before your child receives Beyfortus, tell your healthcare provider about all of your child’s medical conditions, including if your child:
Tell your healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your infant should not receive a medicine called palivizumab if they have already received Beyfortus in the same RSV season.
Serious allergic reactions have happened with other medicines like Beyfortus. Get medical help right away if your child has any of the following signs or symptoms of a serious allergic reaction:
The most common side effects of Beyfortus include rash and pain, swelling, or hardness at the site of your child’s injection. These are not all the possible side effects of Beyfortus. Call your healthcare provider if you have questions about side effects.
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Evan Berland | +1 215 432 0234 | email@example.com